Mucormycosis in Diabetic Patients: Clinical Spectrum, Management Strategies, and Treatment Outcomes at a Tertiary Care Center
DOI:
https://doi.org/10.52206/jsmc.2026.16.1.1062Abstract
Background: Mucormycosis is a rare but aggressive opportunistic fungal infection that predominantly affects immunocompromised individuals, particularly patients with diabetes mellitus. Poor glycemic control creates a favorable environment for fungal proliferation, leading to rapid disease progression and high mortality. The rising incidence of mucormycosis among diabetic patients highlights the need for a detailed evaluation of its clinical presentation, management strategies, and outcomes.
Objective: To assess the clinical features, diagnostic approaches, management strategies, and treatment outcomes of mucormycosis among diabetic patients presenting to the Department of ENT, Hayatabad Medical Complex, Peshawar.
Methodology: A retrospective observational cohort study was conducted involving 250 diabetic patients diagnosed with mucormycosis between June 2023 and June 2024. Data were collected from medical records, including demographic characteristics, clinical presentation, diagnostic modalities, treatment strategies, and outcomes. A prospective follow-up of six months was performed to evaluate recovery and mortality. Statistical analysis was carried out using SPSS version 25.0, with significance set at p < 0.05.
Results: The rhino-orbital-cerebral form was the most common clinical presentation, affecting 72% of patients. Pulmonary, cutaneous, and disseminated forms were less frequent. Complete recovery was observed in 40%, partial recovery in 36%, while 24% of patients died. Uncontrolled diabetes showed a statistically significant association with increased disease severity and mortality.
Conclusion: Mucormycosis represents a serious and often fatal complication among diabetic patients, particularly those with poor glycemic control. Early diagnosis, aggressive antifungal therapy, timely surgical intervention, and stringent diabetes management are critical to improving patient outcomes. These findings provide valuable insight for optimizing clinical management strategies in resource-limited settings.
Keywords: Diabetes Mellitus, Glycemic Control, Mucormycosis, Rhino-Orbital-Cerebral, Treatment Outcomes.
References
Coste A, Conrad A, Porcher R, Poirée S, Peterlin P, Defrance C, et al. improving diagnosis of pulmonary mucormycosis: leads from a contemporary national study of 114 cases. Chest 2023. https://doi.org/10.1016/j.chest.2023.06.039
Özbek L, Topcu U, Manay M, Esen B, Bektas SN, Ayd?n S, et al. covid-19–associated mucormycosis: a systematic review and meta-analysis of 958 cases. Clin Microbiol Infect 2023;29:722–31. https://doi.org/10.1016/j.cmi.2023.03.008
Muthu V, Agarwal R, Dhooria S, Sehgal I, Prasad K, Aggarwal A, et al. has the mortality from pulmonary mucormycosis changed over time? a systematic review and meta-analysis. Clin Microbiol Infect 2021. https://doi.org/10.1016/j.cmi.2020.12.035
Sharma A, Goel A. mucormycosis: risk factors, diagnosis, treatments, and challenges during covid-19 pandemic. Folia Microbiol (Praha) 2022;67:363–87. https://doi.org/10.1007/s12223-021-00934-5
Salehi M, Mahmoudi S, Rezahosseini O, Hashemi SJ, Ahmadikia K, Aala F, et al. the epidemiological, clinical, mycological, and pathological features of rhino-cerebral mucormycosis: a systematic review. Iran J Pathol 2022;17:112–21. https://doi.org/10.30699/ijp.2022.538690.2721
Hoenigl M, Seidel D, Carvalho A, Rudramurthy S, Arastehfar A, Gangneux J, et al. the emergence of covid-19 associated mucormycosis: a review of cases from 18 countries. The Lancet Microbe 2022;3. https://doi.org/10.1016/s2666-5247(21)00237-8
Joshi S, Telang R, Tambe M, Havaldar R, Sane M, Shaikh A, et al. outbreak of mucormycosis in coronavirus disease patients, pune, india. Emerg Infect Dis 2021;28:1–8. https://doi.org/10.3201/eid2801.211636
Manesh A, Devasagayam E, Bhanuprasad K, Varghese L, Kurien R, Cherian L, et al. short intravenous amphotericin b followed by oral posaconazole using a simple, stratified treatment approach for diabetes or covid-19 associated rhino-orbito-cerebral mucormycosis: a prospective cohort study. Clin Microbiol Infect 2023. https://doi.org/10.1016/j.cmi.2023.06.017
Rothe K, Braitsch K, Okrojek R, Heim M, Rasch S, Verbeek M, et al. clinical and microbiological features and outcomes of mucormycosis in critically ill patients. Int J Infect Dis 2021;109:142–7. https://doi.org/10.1016/j.ijid.2021.06.066
Arora U, Priyadarshi M, Katiyar V, Soneja M, Garg P, Gupta I, et al. risk factors for coronavirus disease-associated mucormycosis. J Infect 2021;84:383–90. https://doi.org/10.1016/j.jinf.2021.12.039
Sahu RK, Salem-Bekhit MM, Bhattacharjee B, Almoshari Y, Ikbal AMA, Alshamrani M, et al. mucormycosis in indian covid-19 patients: insight into its patho-genesis, clinical manifestation, and management strategies. Antibiotics 2021;10. https://doi.org/10.3390/antibiotics10091079
Watanabe A, So M, Mitaka H, Ishisaka Y, Takagi H, Inokuchi R, et al. clinical features and mortality of covid-19-associated mucormycosis: a systematic review and meta-analysis. Mycopathologia 2022;187:271–89. https://doi.org/10.1007/s11046-022-00627-8
Fathima AS, Mounika VL, Kumar VU, Gupta AK, Garapati P, Ravichandiran V, et al. mucormycosis: a triple burden in patients with diabetes during covid-19 pandemic. Heal Sci Rev 2021;1:100005. https://doi.org/10.1016/j.hsr.2021.100005
Shakir M, Maan MHA, Waheed S. mucormycosis in a patient with covid-19 with uncontrolled diabetes. BMJ Case Rep 2021;14. https://doi.org/10.1136/bcr-2021-245343
Patel A, Agarwal R, Rudramurthy S, Shevkani M, Xess I, Sharma R, et al. multicenter epidemiologic study of coronavirus disease–associated mucormycosis, india. Emerg Infect Dis 2021;27:2349–59. https://doi.org/10.3201/eid2709.210934
Additional Files
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 The authors retain the copyrights. Authors are permitted and encouraged to post their work online (e.g. in institutional repositories or on their website), as it can lead to productive exchanges, as well as greater citation of published work.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
